NasdaqGM:ADMABiotechs
Will ADMA Biologics' (ADMA) Expanded Credit Line Shift Its Long-Term Growth and Capital Allocation Plans?
In early August 2025, ADMA Biologics reported increased revenue and net income for the second quarter, reaffirmed its revenue guidance for 2025 and 2026, secured a new US$300 million credit agreement, and completed a US$14.98 million share buyback.
A key takeaway is that the company’s expanded financial resources and reaffirmed long-term outlook signal a continued commitment to both operational growth and shareholder value initiatives.
We’ll examine how the new US$300 million credit facility...